You are here: Industry Insights > trial

News List

More Alzheimer's Drug Trial Failures: Are Researchers on the Wrong Track? drugs
April 11, 2019
Amyloid beta has long been a prime suspect in Alzheimer's disease, since abnormal levels of the protein form disruptive plaques between patients' brain cells...
GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial americanpharmaceuticalreview
April 11, 2019
GT Biopharma Receives Institutional Review Board Approval to Proceed With in Human FDA Phase 1 Clinical Trial.
Australia conducts trial to test new brain reading device biospectrumasia
April 10, 2019
The research is being supported by Synchron Pty Ltd, an Australian Neurotechnology Company.
Alzheimer’s trial discontinued due to inefficiency pharmatimes
March 27, 2019
Biogen and Eisai have stopped two global Phase III trials of the Alzheimer's drug aducanumab, after interim analyses indicated that the agent was ineffective and would not meet the primary endpoint.
Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody en-cphi.cn
March 21, 2019
Innovent Biologics announced that the first patient has been successfully dosed in a Phase IIa clinical study of IBI306...
Allergy Therapeutics’ birch pollen product fails to meet primary endpoint pharmaceutical-technology
March 20, 2019
UK-based Allergy Therapeutics has announced that its new adjuvanted allergoid product indicated for birch pollen-induced seasonal allergic rhinitis failed to meet the primary endpoint in the Phase III B301 trial.
OncoImmune Announces Completion of Phase II Trial americanpharmaceuticalreview
January 11, 2019
OncoImmune has completed its Phase IIa trial of CD24Fc for the Prevention of Acute GVHD Following Myeloablative Allogeneic HSCT.
Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200 americanpharmaceuticalreview
January 10, 2019
Forbius announced the first patient was dosed in a Phase 1 clinical trial with AVID200. The trial will evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor effects of escalating doses of AVID200 in patients with solid tumors.....
Green light for Amryt's epidermolysis bullosa study pharmatimes
January 08, 2019
An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 - a potential treatment for the currently incurable Epidermolysis Bullosa (EB) - should continue.
Vectura pulls the plug on experimental asthma therapy contractpharma
November 28, 2018
Vectura says it no longer plans to develop and partner experimental asthma therapy VR475, after it failed to hit Phase III targets.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page